We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News

Executive Summary

A letter signed by the entire Senate committee questions CMS’ reasons for dropping antidepressants and antipsychotic drugs from protected status in the Medicare Part D program, arguing it could end up increasing costs to the program.